TLC Announces Full Patient Enrollment in EXCELLENCE Trial of TLC599 for Osteoarthritis PainOn-schedule completion of enrollment despite COVID-19 pandemic; unique trial design evaluates safety and efficacy of single & repeat doses
The Pharma Data
DECEMBER 27, 2020
We remain confident that results from this trial will be positive given the outstanding results observed in our Phase II clinical trial.”. Current intraarticular anti-inflammatory treatments for OA have potentially toxic side effects and may lead to the destruction of cartilage filler proteins. SOUTH SAN FRANCISCO, Calif. About TLC599.
40 
Let's personalize your content